MedTrace Logo

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

NCT04209686 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-12-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and clinical activity of paclitaxel plus olaparib and pembrolizumab in patients with previously treated advanced Gastric Cancer (GC).

Conditions

  • Advanced Gastric Adenocarcinoma

Interventions

DRUG

Paclitaxel

1. Patients will receive treatment on Day 1 and 8 starting with cycle 2. 2. Paclitaxel (80 mg) will be administered IV on days 1 and 8 starting with cycle 2 (every 21 days). 3. Drug - Paclitaxel - 80mg IV

DRUG

Olaparib

1. Olaparib will be taken by mouth daily for 3 weeks (every 21 days). 2. Drug - 100 mg or 300mg

DRUG

Pembrolizumab

1. Patients will receive treatment every 21 days. 2. Pembrolizumab (200 mg) will be administered IV on day 1 (every 21 days). 3. Drug - 200mg IV

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Katherine Bever, MD · Johns Hopkins Medical Institution

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2028-09-01
Completion
2028-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04209686 on ClinicalTrials.gov